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ABSTRACT
Chronic kidney disease (CKD) is one of the fastest growing causes of death worldwide. Only early diagnosis will allow
prevention of both CKD progression and the negative impact of CKD on all-cause and cardiovascular mortality. Klotho is a
protein produced by the kidneys that has anti-ageing and phosphaturic properties, preventing excess positive phosphate
balance. There is evidence that Klotho downregulation is one of the earliest consequences of kidney injury. Thus the
development of reliable assays to monitor Klotho levels may allow an early diagnosis of CKD and monitoring the impact of
therapies aimed at preserving Klotho expression or at preventing CKD progression. However, the performance of Klotho
assays has been suboptimal so far. In this issue of Clinical Kidney Journal, Neyra et al. explore methods to improve the
reliability of Klotho assays.
Keywords: blind spot, chronic kidney disease, Klotho, proteomics
In 1997, Kuro-O et al. [1] described Klotho as a novel protein
mainly synthetized by the kidneys, which had anti-ageing prop-
erties. It was later shown that protection from excess dietary
phosphate intake was a key element in the anti-ageing effects
of Klotho [2]. This was related to both direct effects on proximal
tubular phosphate transporters, promoting phosphaturia [3],
and on its role as a co-receptor for fibroblast growth factor 23
(FGF23), also in proximal tubular cells [4]. Further studies dis-
closed that both acute kidney injury (AKI) and chronic kidney
disease (CKD) are conditions of acquired Klotho deficiency [5].
Indeed, several of the features of genetic Klotho deficiency,
such as bone disease, vascular calcification, left ventricular hy-
pertrophy, premature mortality, increased FGF23 levels and
hyperphosphataemia, among others, are also features of CKD, a
syndrome with a negative impact on multiple organs and sys-
tems that has been characterized as a syndrome of accelerated
ageing [6, 7]. The widespread consequences of Klotho deficiency
have led to the proposal that Klotho acts as an integrator of or-
gan systems [8]. Given this background, it was widely expected
that assessment of Klotho levels in biological fluids might pro-
vide useful information for risk stratification or patient catego-
rization. However, this has not been the case and the literature
has often been contradictory. In contrast, circulating FGF23 is
convincingly associated with adverse outcomes [9], and preclin-
ical studies have shown that kidney-specific Klotho deficiency
reproduces the phenotype of Klotho-deficient animals, includ-
ing very low circulating Klotho levels and extremely high circu-
lating FGF23 levels [10].
KLOTHO DEFICIENCY: THE FIRST
MANIFESTATION OF KIDNEY DYSFUNCTION
AND A DRIVER OF DISEASE PROGRESSION?
The issue acquires further relevance as there is evidence that
Klotho deficiency develops in very early stages of CKD as a re-
sponse to pathological albuminuria, kidney inflammation or
even systemic inflammation at a distant organ site that influen-
ces the biology of a healthy kidney [11–13]. Thus a reliable
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assessment of Klotho levels and the identification of biological
fluid (plasma/serum versus urine) more reliable for assessing
kidney Klotho production could potentially be a game-changing
development that influences the way we define or categorize
CKD. This would be part of a wider trend towards earlier diagno-
sis of CKD, including the development of a urine peptidomics
classifier such as CKD273 or modifications of it that allow the
risk stratification for progression of CKD even in patients who
do not fulfil the current criteria to diagnose CKD (i.e. pathologi-
cal albuminuria or decreased glomerular filtration rate) [14, 15].
Indeed, some of the most reliable evidence of an early de-
crease in kidney Klotho is derived from the analysis of urine
Klotho by either immunoprecipitation–immunoblotting (IP–IB)
or immunoblotting [11, 16]. While in the specific patients stud-
ied, the driver of decreased urinary Klotho levels in early CKD
(A2–A3, G1–G2) is open to question, preclinical evidence indi-
cates that decreased urinary Klotho indeed reflects low kidney
Klotho gene and protein expression [11].
HOW DO FINDINGS BY NEYRA ET AL. FIT IN?
Neyra et al. [17] have addressed the discrepancies in the
reported relationship between circulating Klotho and kidney
disease in this issue of Clinical Kidney Journal. They found that
IP–IB appears to provide a reliable assessment of Klotho levels
in fresh or only once-thawed serum. In contrast, one of the
most widely used enzyme-linked immunosorbent assays
(ELISAs) was unreliable in detecting exogenously added recom-
binant Klotho, and serum Klotho levels assessed by ELISA did
not correlate with glomerular filtration rate (GFR) (r¼ 0.18, P ¼
NS), as opposed to the significant correlation found between
Klotho IP–IB and estimated GFR (eGFR) values (Klotho: r¼ 0.80,
P< 0.001). An intriguing finding was that the recovery of exoge-
nous Klotho was lower in uraemic serums, suggesting that
uraemia-specific factors may decrease Klotho protein levels or
antigenicity. No modification of the sample processing protocol
improved the ELISA reliability. A significant correlation between
ELISA Klotho and IP–IB Klotho was observed, although the
strength of the association was suboptimal (r¼ 0.28, P¼ 0.01).
This is bad news for the advance of the Klotho field since IP–IB
is a time-consuming technique, not appropriate for large stud-
ies. Furthermore, it was found that the quality of specific anti-
body batches may also influence the results. While other
authors have found an association of pathological albuminuria
with decreased urinary Klotho, as assessed by IB in fresh urine
[11], Neyra et al. [17] did not assess the impact of albuminuria on
serum Klotho or the combined impact of eGFR and albuminuria
on circulatory Klotho levels. Indeed, most albuminuria values in
their samples were within the physiological range and just 25%
of the values within the one cohort that collected these values
were >41 mg/g urinary creatinine.
CONCLUSIONS
Clearly, more reliable, high-throughput ways to assess kidney
Klotho production or Klotho levels in biological fluids should be
developed, including testing the feasibility of proteomics tech-
niques, such as multiple reaction monitoring/selective reaction
monitoring. The development of assays and subsequent routine
monitoring of Klotho levels or production may address the so-
called blind spot in CKD [18] (Figure 1). This is an early stage in
the natural history of CKD when the kidneys are already dam-
aged but eGFR and albuminuria do not yet meet the thresholds
to diagnose CKD and no other CKD diagnostic criteria is yet met.
The proof-of-concept for the existence of the blind spot in CKD
is autosomal dominant polycystic kidney disease in which, in
the absence of imaging, CKD cannot be diagnosed for decades.
The search is on for ‘imaging-like’ techniques that shed light on
early stages of CKD in non-polycystic CKD and reliable assess-
ment of Klotho levels may be one such technique.
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FIGURE 1: The CKD blind spot. (A) CKD blind spot. The most frequently used di-
agnostic and risk categorization criteria for CKD are GFR and urinary
albumin:creatinine ratio (UACR). However, they represent late events, allowing
for a blind spot in the diagnosis of CKD, which may last for years. This blind
spot is characterized by the progression of undiagnosed kidney injury, that is,
by progressive loss of GFR or progressive increase in albuminuria, but yet within
limits that are not diagnostic of CKD. As it is the case with driving, a blind spot
may be fatal since specific therapy may be initiated too late to prevent the need
for renal replacement therapy or premature death. The CKD blind spot is col-
oured pink in the image. (B) Imaging addresses the blind spot in autosomal
dominant polycystic kidney disease, allowing the identification of multiple bi-
lateral cysts and the diagnosis of CKD decades before GFR or UACR become
pathological. (C) If reliable biological fluid processing and Klotho assessment
methods are developed, and suggestions of an early decrease of Klotho follow-
ing kidney injury are confirmed, assessment of Klotho levels may potentially
provide an earlier diagnosis of CKD than either GFR or UACR. (A) and (B) repro-
duced by Sanchez-Ni~no et al. [18].
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